Literature DB >> 18855981

Antitumor bioactivity of adenovirus-mediated p27mt in colorectal cancer cell line SW480.

Ze-Qun Sun1, Chang-Sheng Deng, Shao-Yong Xu, Yong Du.   

Abstract

AIM: To explore the antitumor bioactivity of adenovirus-mediated mutant type p27(kip1) gene in a colorectal cancer cell line SW480.
METHODS: We constructed recombinant adenovirus vector expressing a mutant type p27(kip1) gene (ad-p27mt), with mutation of Thr-187/Pro-188 (ACGCCC) to Met-187/Ile-188 (ATGATC), and transduced into SW480 cells. Then we detected expression of p27, Bcl-2 and Bax protein in the transductants by Western blotting, cell cycle of transductants by a digital flow cytometric system, migrating potential with Boyden Chamber and SW480 tumor cell growth inhibition in vitro and in vivo.
RESULTS: We found that a recombinant adenovirus vector of expressing ad-p27mt, with mutation of Thr-187/Pro-188 (ACGCCC) to Met-187/Ile-188 (ATGATC) has potent inhibition of SW480 tumor cell growth in vitro and in vivo. Furthermore, ad-p27mt induced cell apoptosis via regulating bax and bcl-2 expressions, and G(1)/S arrest in SW480 cells and inhibited cell migration.
CONCLUSION: ad-p27mt has a strong anti-tumor bioactivity and has the potential to develop into new therapeutic agents for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855981      PMCID: PMC2751892          DOI: 10.3748/wjg.14.5827

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

2.  The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury.

Authors:  V Ophascharoensuk; M L Fero; J Hughes; J M Roberts; S J Shankland
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Adenoviral expression of the cyclin-dependent kinase inhibitor p27Kip1: a strategy for breast cancer gene therapy.

Authors:  A N Rakkar; Z Li; Y Katayose; M Kim; K H Cowan; P Seth
Journal:  J Natl Cancer Inst       Date:  1998-12-02       Impact factor: 13.506

4.  Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.

Authors:  Y Katayose; M Kim; A N Rakkar; Z Li; K H Cowan; P Seth
Journal:  Cancer Res       Date:  1997-12-15       Impact factor: 12.701

5.  A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells.

Authors:  C Craig; R Wersto; M Kim; E Ohri; Z Li; D Katayose; S J Lee; J Trepel; K Cowan; P Seth
Journal:  Oncogene       Date:  1997-05-15       Impact factor: 9.867

6.  Cyclin E-CDK2 is a regulator of p27Kip1.

Authors:  R J Sheaff; M Groudine; M Gordon; J M Roberts; B E Clurman
Journal:  Genes Dev       Date:  1997-06-01       Impact factor: 11.361

7.  Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity.

Authors:  M Schreiber; W J Muller; G Singh; F L Graham
Journal:  Oncogene       Date:  1999-03-04       Impact factor: 9.867

8.  Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma.

Authors:  H Mineta; K Miura; I Suzuki; S Takebayashi; H Amano; K Araki; H Harada; K Ichimura; J P Wennerberg; M R Dictor
Journal:  Cancer       Date:  1999-03-01       Impact factor: 6.860

9.  Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1.

Authors:  K Tomoda; Y Kubota; J Kato
Journal:  Nature       Date:  1999-03-11       Impact factor: 49.962

10.  p27Kip1 overexpression causes apoptotic death of mammalian cells.

Authors:  X Wang; M Gorospe; Y Huang; N J Holbrook
Journal:  Oncogene       Date:  1997-12-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.